Epidemiology and Biomarker Study in Alzheimer's Disease

Recruiting now · Phase 3

Conditions studied: Alzheimer Disease

In brief

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

Key facts

Study ID

NCT07142954

Run by

Eli Lilly and Company

People needed

3400

Starts

2025-08-25

Expected to finish

2033-07-01

Last updated by the study team

2026-07-07

Who can join

Age: 55 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The participant must self-report unimpaired cognition.
• The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.

You may not qualify if…

• Have seen a doctor about memory concerns.
• Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
• Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
• Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.

Where it is running

• Care Access - Houston — Houston, Texas, United States (enrolling)
• The University of Tokyo Hospital — Bunkyō City, Japan (enrolling)
• Souseikai Sumida Hospital — Tokyo, Japan (enrolling)
• Higashi Shinjuku Clinic — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.